China-based startup Canton Biologics recently completed a Series C financing round exceeding 300 million yuan. This round of financing was led by SDIC Venture Capital, with participation from Guangdong Technology Financial Group, Taipu Life Science Investment, and Chnin Financial.

The funds raised in this round will be channeled towards advancing the company's R&D in novel biotechnologies, scaling commercial production capabilities, and expanding its global strategic footprint.

Founded in Guangzhou in 2016, Canton Biologics specialises in the large molecule biopharmaceutical contract development and manufacturing organisation (CDMO) sector, offering end-to-end services from biopharmaceutical CMC development to commercial production and global clinical supply.

The company has made significant advancements in the lgM molecule expression platform, expression host cells, high-density cell culture, new formulations, and analytical methodologies. Canton Biologics has emerged as a flagship entity in the large molecule drug CDMO sphere, with extensive expertise and robust technical foundations in areas such as proprietary cell line development, pre-clinical pharmaceutical formulation, large-scale commercial manufacturing, and integrated clinical supply chain management.